The influence of Actinobacillus pleuropneumoniae infection on tulathromycin pharmacokinetics and lung tissue disposition in pigs.
A tulathromycin concentration and pharmacokinetic parameters in plasma and lung tissue from healthy pigs and Actinobacillus pleuropneumoniae (App)-infected pigs were compared. Tulathromycin was administered intramuscularly (i.m.) to all pigs at a single dose of 2.5 mg/kg. Blood and lung tissue samples were collected during 33 days postdrug application. Tulathromycin concentration in plasma and lung was determined by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. The mean maximum plasma concentration (Cmax ) in healthy pigs was 586 ± 71 ng/mL, reached by 0.5 h, while the mean value for Cmax of tulathromycin in infected pigs was 386 ± 97 ng/mL after 0.5 h. The mean maximum tulathromycin concentration in lung of healthy group was calculated as 3412 ± 748 ng/g, detected at 12 h, while in pigs with App, the highest concentration in lung was 3337 ± 937 ng/g, determined at 48 h postdosing. The higher plasma and lung concentrations in pigs with no pulmonary inflammation were observed at the first time points sampling after tulathromycin administration, but slower elimination with elimination half-life t1/2el  = 126 h in plasma and t1/2el  = 165 h in lung, as well as longer drug persistent in infected pigs, was found.
Department of Pharmacology and Toxicology, National Veterinary Research Institute, Pulawy, Poland.
A
A
Gajda
Department of Pharmacology and Toxicology, National Veterinary Research Institute, Pulawy, Poland.
T
T
Bladek
Department of Pharmacology and Toxicology, National Veterinary Research Institute, Pulawy, Poland.|Department of Swine Diseases, National Veterinary Research Institute, Pulawy, Poland.
A
A
Jablonski
Department of Pharmacology and Toxicology, National Veterinary Research Institute, Pulawy, Poland.
A
A
Posyniak
D000189:Actinobacillus Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae; D000818:Animals; D004187:Disaccharides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000382:microbiology; D014018:Tissue Distribution; D018942:Macrolides
D004187:Disaccharides; D006571:Heterocyclic Compounds; C485204:tulathromycin; D018942:Macrolides